RE: Results20 Oct 2022 08:22
Brian Tenner, Nanoco's CEO, commented on the results:
"We have consistently delivered on all of our target milestones throughout the Period. The full year contract with the European electronics customer covers product validation and new material development. This is a clear sign of their commitment to commercialising infra-red sensors using Nanoco's quantum dots. We maintain our goal of being ready in H1 FY23 for potential commercial production orders in the short term.
"Interest has been re-energised in our CFQDs for use in displays. This reflects the gradually increasing number of panel makers seeking cadmium free solutions and also reflects the strong underpinning of Nanoco's IP provided by the PTAB decisions earlier this year.
"We are consolidating our core R&D and scale up capabilities in our Runcorn production facility to deliver sustainable net savings of around £0.7m p.a. The over-subscribed equity fund raise significantly extended the cash runway beyond when we expect to be self-financing. This has also allowed targeted strategic investments in new equipment and additional personnel as we increase our overall activity levels across the business, including new R&D staff to support new materials for other quantum applications.
"We are also pleased with the developments in our litigation against Samsung during the Period. The progress vindicates and enhances our confidence in the merits of our case. We won all five of the inter partes reviews at PTAB. At the pre-trial conference, the motions that are important to Nanoco were resolved in our favour. We have been able to narrow our focus ahead of the short one week trial onto those claims that Nanoco considers to be the strongest and most clearly infringed. We patiently await a confirmed date for that trial.
"The whole Nanoco team has worked hard to deliver significant progress on a number of fronts during the year. We have increased the potential to create significant shareholder value in our organic activities and the Samsung litigation in the short to medium term. We will be working hard to continue these trends, particularly with confidence in the visibility of commercial production orders and an initial outcome to the trial in Texas during H1 FY23. The Board therefore has growing confidence in the strength of the investment proposition and value inherent in the business."